Entries by Max

Beyond the Primary Target: How DeepTarget Rewrites Mechanism Discovery in Cancer

/in /by

The modern small‑molecule rarely acts through a single, invariant target, and DeepTarget is a new computational framework that embraces this reality by mapping both direct and indirect anti‑cancer mechanisms across diverse cellular contexts. Developed by researchers at Sanford Burnham Prebys and collaborators, DeepTarget integrates large‑scale drug viability screens, genome‑wide CRISPR knockout data, and matched omics […]

EVOLUTION Trial Ipilimumab And Nivolumab Plus 177Lu‑PSMA‑617 in mCRPC

/in , , /by

Phase II EVOLUTION is a randomized study testing whether adding ipilimumab and nivolumab to 177Lu‑PSMA‑617 improves outcomes versus 177Lu‑PSMA‑617 alone in men with metastatic castration‑resistant prostate cancer (mCRPC). Early data presented in 2025 indicate that at 12 months, 33% of patients on the combination were free of progression versus 17% on 177Lu‑PSMA‑617 alone, signaling a […]

Newsletter 46/2025

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Another week of promising clinical and preclinical trials. And I’m letting you know that, at your suggestion, I’m working on a mega table of all the clinical trials I’ve discussed, so you’ll have a quick reference for what’s happening […]

New Trial for AMO959 and Pluvicto and ARSI Combo

/in , , , /by

The ongoing phase Ib/II trial investigating the combination of AMO959, Pluvicto (lutetium-177 vipivotide tetraxetan, also known as AAA617 or 177Lu-PSMA-617), and androgen receptor pathway inhibitors (ARPIs) in metastatic castration-resistant prostate cancer (mCRPC) explores a novel approach targeting disease through multiple pathways. AMO959 is a direct activator of AMPK, a key metabolic regulator that can disrupt […]

Pacritinib in Participants With mCRPC Expressing Stat5 (POSTPONE)

/in , , /by

To join the phase 2 POSTPONE trial investigating pacritinib for advanced prostate cancer, patients must have metastases that are strongly positive for STAT5 activation—specifically, a recent tumor biopsy must show detectable nuclear STAT5 in more than 5% of cancer cells.​ This trial is built upon robust laboratory and clinical findings showing that the JAK2-STAT5 pathway […]

A Phase 3 Study of Pasritamig Plus Docetaxel

/in , , /by

Pasritamig is a bispecific T-cell engager that targets human kallikrein 2 (KLK2), a protein found primarily in prostate tissue and often retained in advanced prostate cancer. This drug brings T cells into close contact with KLK2-expressing tumor cells, directing immune responses against the cancer. In phase 1 studies, pasritamig was evaluated in men with metastatic […]

Dr. Sartor Explains the ARTISAN Trial

/in /by

In a recent presentation, Dr. Oliver Sartor highlighted Lead-212 (Pb-212) as a promising next step in precision radioligand therapy for metastatic castration-resistant prostate cancer. Developed by the same Oslo-based team that introduced Radium-223, Lead-212 is being studied in the ARTISAN (AB001) trial and represents a significant evolution in alpha-emitting radiopharmaceuticals. Its defining features are a […]

CBPD‑409, an Oral CBP/p300 Degrader for Advanced Prostate Cancer

/in , /by

CBPD‑409 is an experimental, oral medicine designed to remove two helper proteins, CBP and p300, that prostate tumors use to turn cancer‑driving genes on. These proteins partner with the androgen receptor (AR), the key signal that fuels most prostate cancers, especially in the advanced, treatment‑resistant setting. By tagging CBP and p300 for destruction, a strategy […]

Newsletter 45/2025

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This week’s photo features me and my better half! (Mine is the hand underneath.) We celebrated our anniversary, and here I am, still full from dinner, finishing up the newsletter! This week, too, we have some exciting updates on […]

Subgroup Analysis of The ARASENS Trial

/in , /by

The ARASENS trial, a large phase 3 study, investigated the impact of adding darolutamide, a novel androgen receptor inhibitor, to the standard treatment of androgen-deprivation therapy (ADT) and docetaxel chemotherapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC). A recent subgroup analysis focused on whether the benefits of this combination extend across age groups. In […]